Pharma Stocks
-
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum
Why Takeda Pharmaceutical Stock Is On Investors’ Radar Takeda Pharmaceutical (TSE:4502) has recently drawn attention after a strong run in…
Read More » -
Defensive Pharma Giant Tests Investors’ Patience As Shares Slip Despite Solid Pipel
GSK plc (ADR) has drifted lower over the past week, even as the British drugmaker pushes deeper into vaccines, HIV…
Read More » -
Is This ‘Boring’ Pharma Stock About To Blow Up?
Gilead Sciences just pulled a quiet power move on Wall Street. Is this sleepy pharma giant a low-key gold mine…
Read More » -
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress
Crinetics Pharmaceuticals (CRNX) has been in focus after a Goldman Sachs analyst upgrade that followed positive Phase 2 data for…
Read More » -
60 Degree Pharma To Implement 1-for-4 Reverse Stock Split To Regain Nasdaq Compliance
(RTTNews) – 60 Degree Pharmaceuticals, Inc. (SXTP) is preparing to consolidate its shares in a one-for-four (1:4) reverse stock split,…
Read More » -
Is Xspray Pharma (STO:XSPRAY) In A Good Position To Deliver On Growth Plans?
There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses…
Read More » -
Defensive Pharma Heavyweight Weighs Litigation Risks Against Pipeline Promise
GSK’s stock has drifted sideways in recent sessions, caught between renewed confidence in its vaccines and HIV franchises and a…
Read More » -
60 Degree Pharmaceuticals Announces One-for-Four Reverse Stock Split Effective January 20, 2026
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”),…
Read More » -
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett…
Read More » -
Marksans Pharma Limited’s (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It’s not a stretch to say that Marksans Pharma Limited’s (NSE:MARKSANS) price-to-earnings (or “P/E”) ratio of 22.2x right now seems…
Read More »